Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Breast Cancer Research
Published in: Breast Cancer Research 4/2005

01-08-2005 | Commentary

Menopausal hormone therapy after breast cancer

Author: Graham A Colditz

Published in: Breast Cancer Research | Issue 4/2005

Login to get access

Abstract

The use of postmenopausal hormone therapy after breast cancer remains controversial. Evidence shows variation by study design, and even among three randomized controlled trials there is substantial heterogeneity of results. Two Swedish trials of comparable size show relative risks of recurrence of 3.3 and 0.82 on comparing women receiving postmenopausal hormone therapy with control women. The extent of use of tamoxifen and concomitant use of progestins in combination with estrogen, although raised as one possible explanation for this heterogeneity, are not supported by evidence from trials of high-dose progestins used after breast cancer. Caution is needed when considering the use of postmenopausal hormone therapy after breast cancer.
Literature
1.
Colditz GA, Hankinson SE, Hunter DJ, Willett WC, Manson JE, Stampfer MJ, Hennekens C, Rosner B, Speizer FE: The use of estrogens and progestins and the risk of breast cancer in postmenopausal women. N Engl J Med. 1995, 332: 1589-1593. 10.1056/NEJM199506153322401.CrossRefPubMed
2.
Beral V: Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet. 2003, 362: 419-427. 10.1016/S0140-6736(03)14596-5.CrossRefPubMed
3.
Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, Jackson RD, Beresford SA, Howard BV, Johnson KC, et al: Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. JAMA. 2002, 288: 321-333. 10.1001/jama.288.3.321.CrossRefPubMed
4.
Coates RJ, Clark WS, Eley JW, Greenberg RS, Huguley CM, Brown RL: Race, nutritional status, and survival from breast cancer. J Natl Cancer Inst. 1990, 82: 1684-1692.CrossRefPubMed
5.
Kroenke CH, Chen WY, Rosner B, Holmes MD: Weight, weight gain, and survival after breast cancer diagnosis. J Clin Oncol. 2005, 23: 1370-1378. 10.1200/JCO.2005.01.079.CrossRefPubMed
6.
Early Breast Cancer Trialists' Collaborative Group: Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised evidence. Lancet. 2005, 365: 1687-1717. 10.1016/S0140-6736(05)66544-0.CrossRef
7.
Col NF, Kim JA, Chlebowski RT: Menopausal hormone therapy after breast cancer: a meta-analysis and critical appraisal of the evidence. Breast Cancer Res. 2005, 7: R535-R540. 10.1186/bcr1035.CrossRefPubMedPubMedCentral
8.
Berlin JA: The benefits of heterogeneity in meta-analysis of data from epidemiologic studies. Invited commentary. Am J Epidemiol. 1995, 142: 383-387.PubMed
9.
Colditz G, Burdick E, Mosteller F: Heterogeneity in meta-analysis of data from epidemiologic studies: a commentary. Am J Epidemiol. 1995, 142: 371-382.PubMed
10.
Hankinson SE, Willett WC, Manson JE, Hunter DJ, Colditz GA, Stampfer MJ, Longcope C, Speizer FE: Alcohol, height, and adiposity in relation to estrogen and prolactin levels in postmenopausal women. J Natl Cancer Inst. 1995, 87: 1297-1302.CrossRefPubMed
11.
Huang Z, Hankinson SE, Colditz GA, Stampfer MJ, Hunter DJ, Manson JE, Hennekens CH, Rosner B, Speizer FE, Willett WC: Dual effects of weight and weight gain on breast cancer risk. JAMA. 1997, 278: 1407-1411. 10.1001/jama.278.17.1407.CrossRefPubMed
12.
Key TJ, Appleby PN, Reeves GK, Roddam A, Dorgan JF, Long-cope C, Stanczyk FZ, Stephenson HE, Falk RT, Miller R, et al: Body mass index, serum sex hormones, and breast cancer risk in postmenopausal women. J Natl Cancer Inst. 2003, 95: 1218-1226.CrossRefPubMed
13.
von Schoultz E, Rutqvist LE: Menopausal hormone therapy after breast cancer: the Stockholm randomized trial. J Natl Cancer Inst. 2005, 97: 533-535.CrossRefPubMed
14.
Holmberg L, Anderson H: HABITS (hormonal replacement therapy after breast cancer – is it safe?), a randomised comparison: trial stopped. Lancet. 2004, 363: 453-455. 10.1016/S0140-6736(04)15493-7.CrossRefPubMed
15.
Benson K, Hartz AJ: A comparison of observational studies and randomized, controlled trials. N Engl J Med. 2000, 342: 1878-1886. 10.1056/NEJM200006223422506.CrossRefPubMed
16.
Concato J, Shah N, Horwitz RI: Randomized, controlled trials, observational studies, and the hierarchy of research designs. N Engl J Med. 2000, 342: 1887-1892. 10.1056/NEJM200006223422507.CrossRefPubMedPubMedCentral
17.
Palmieri D, Halverson DO, Ouatas T, Horak CE, Salerno M, Johnson J, Figg WD, Hollingshead M, Hursting S, Berrigan D, et al: Medroxyprogesterone acetate elevation of Nm23-H1 metastasis suppressor expression in hormone receptor-negative breast cancer. J Natl Cancer Inst. 2005, 97: 632-642.CrossRefPubMed
18.
Focan C, Beauduin M, Salamon E, de Greve J, de Wasch G, Lobelle JP, Majois F, Tagnon A, Tytgat J, van Belle S, et al: Adjuvant high-dose medroxyprogesterone acetate for early breast cancer: 13 years update in a multicentre randomized trial. Br J Cancer. 2001, 85: 1-8. 10.1054/bjoc.2001.1829.CrossRefPubMedPubMedCentral
19.
Hupperets PS, Wils JA, Volovics L, Schouten LJ, Fickers MM, Bron HN, Jager JJ, de Jong JM, Blijham GH: Adjuvant chemohormonal therapy with cyclophosphamide, doxorubicin and 5-fluorouracil (CAF) with or without medroxyprogesterone acetate (MPA) for node-positive cancer patients, update at 12 years follow up. Breast. 2001, 10: 35-37. 10.1054/brst.2000.0180.CrossRefPubMed
20.
Stockler M, Wilcken NR, Ghersi D, Simes RJ: Systematic reviews of chemotherapy and endocrine therapy in metastatic breast cancer. Cancer Treat Rev. 2000, 26: 151-168. 10.1053/ctrv.1999.0161.CrossRefPubMed
21.
Chlebowski RT, Hendrix SL, Langer RD, Stefanick ML, Gass M, Lane D, Rodabough RJ, Gilligan MA, Cyr MG, Thomson CA, et al: Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: the Women's Health Initiative Randomized Trial. JAMA. 2003, 289: 3243-3253. 10.1001/jama.289.24.3243.CrossRefPubMed
22.
Anonymous: Treatment of estrogen deficiency symptoms in women surviving breast cancer. The Hormone Foundation, Canadian Breast Cancer Research Initiative, National Cancer Institute of Canada, Endocrine Society, and the University of Virginia Cancer Center and Woman's Place. J Clin Endocrinol Metab. 1998, 83: 1993-2000. 10.1210/jc.83.6.1993.CrossRef
23.
Marsden J, Whitehead M, Hern RA, Baum M, Sacks N: Are randomized trials of hormone replacement therapy in symptomatic women with breast cancer feasible?. Fertil Steril. 2000, 73: 292-199. 10.1016/S0015-0282(99)00510-5.CrossRefPubMed
Metadata
Title
Menopausal hormone therapy after breast cancer
Author
Graham A Colditz
Publication date
01-08-2005
Publisher
BioMed Central
Published in
Breast Cancer Research / Issue 4/2005
Electronic ISSN: 1465-542X
DOI
https://doi.org/10.1186/bcr1272

Other articles of this Issue 4/2005

Breast Cancer Research 4/2005 Go to the issue

Research article

Designing a HER2/neupromoter to drive α1,3galactosyltransferase expression for targeted anti-αGal antibody-mediated tumor cell killing

Research article

TP53-binding protein variants and breast cancer risk: a case-control study

Review

Imaging in breast cancer: Single-photon computed tomography and positron-emission tomography

Research article

Connexin 43 mediated gap junctional communication enhances breast tumor cell diapedesis in culture

Viewpoint

Estrogen-repressed genes – key mediators of estrogen action?

Research article

Overexpression of β1-chain-containing laminins in capillary basement membranes of human breast cancer and its metastases
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits